Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Change in Acquisitions & Divestments (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Change in Acquisitions & Divestments for 3 consecutive years, with $24.1 million as the latest value for Q4 2025.

  • Quarterly Change in Acquisitions & Divestments fell 4.49% to $24.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $101.3 million through Dec 2025, down 24.97% year-over-year, with the annual reading at $101.3 million for FY2025, 24.97% down from the prior year.
  • Change in Acquisitions & Divestments hit $24.1 million in Q4 2025 for Compass Therapeutics, up from $13.9 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $59.2 million in Q1 2023 to a low of $13.9 million in Q3 2025.
  • Historically, Change in Acquisitions & Divestments has averaged $34.9 million across 3 years, with a median of $35.4 million in 2023.
  • Biggest five-year swings in Change in Acquisitions & Divestments: increased 0.44% in 2024 and later plummeted 59.52% in 2025.
  • Year by year, Change in Acquisitions & Divestments stood at $51.4 million in 2023, then tumbled by 50.91% to $25.2 million in 2024, then dropped by 4.49% to $24.1 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for CMPX at $24.1 million in Q4 2025, $13.9 million in Q3 2025, and $26.8 million in Q2 2025.